Company Research Report: Deciphera Pharmaceuticals, Inc.
Company Overview
Name and Mission
- Name: Deciphera Pharmaceuticals, Inc.
- Mission: Inspired by patients: Defeat Cancer™. The company is steadfast in its mission to improve the lives of people living with cancer through innovative medicinal developments.
Founding Details
- Founded: 2003
- Founder: Daniel L. Flynn, Ph.D.
Key People
- Ryota Udagawa - President, Chief Executive Officer
- Lisa Amaya Price - Senior Vice President and Chief Human Resources Officer
- Kevin Brodbeck, Ph.D. - Senior Vice President, Technical and Development Operations
- Kelley Dealhoy - Senior Vice President and Chief Business Officer
- Dushyant Dhanak, Ph.D. - Executive Vice President, Chief Scientific Officer
- Margarida Duarte - Executive Vice President, Global Chief Commercial Officer
- Peter Habura - Senior Vice President of Regulatory, Quality & Medical Writing
- Jenn Larson, CPA - Senior Vice President, Chief Financial Officer
- Maria Ostrovsky - Senior Vice President, General Counsel
- Matthew L. Sherman, M.D. - Executive Vice President, Chief Medical Officer
Headquarters
- Location: Waltham, Massachusetts, USA
- Research Facilities: Lawrence, Kansas
Employees and Revenue
- Number of Employees: No information available.
- Revenue: No information available.
Notability
- Deciphera is known for developing switch-control kinase inhibitors, aiming to combat various types of cancers.
Products
Product Overview
1. Ripretinib (QINLOCK®)
- An approved oral KIT and PDGFRA switch-control kinase inhibitor for treating gastrointestinal stromal tumor (GIST).
- Specifically designed to inhibit full spectrum of mutations associated with GIST, providing better treatment to patients.
2. Vimseltinib
- An investigational, oral switch-control tyrosine kinase inhibitor for the treatment of tenosynovial giant cell tumor (TGCT).
- Highly specific to CSF1R, aiming to provide targeted treatment.
3. DCC-3116
- A selective ULK inhibitor designed to inhibit autophagy in cancer cells, particularly those caused by RAS/RAF mutations.
- Currently in Phase 1 studies, exploring its potential when combined with other pathway inhibitors.
4. DCC-3084 and DCC-3009
- Pan-RAF and Pan-KIT inhibitors under development for potentially treating various solid tumors and hematologic malignancies.
Key Features
- Ripretinib: Offers a broad coverage of known mutations making it a significant choice for specific GIST types.
- Vimseltinib: Targets a specific receptor kinase (CSF1R) known to be involved in TGCT pathophysiology.
- DCC-3116: A novel approach targeting autophagy, a known survival mechanism in various cancer types.
Recent Developments
Approvals and Regulatory Submissions
- August 15, 2024: The U.S. FDA accepted for priority review Deciphera’s New Drug Application for Vimseltinib in TGCT treatment.
- July 18, 2024: The European Medicines Agency accepted Deciphera’s Marketing Authorization Application for Vimseltinib.
Acquisition
- June 11, 2024: Completion of acquisition by ONO Pharma, making Deciphera a wholly-owned subsidiary.
Product Developments
- Vimseltinib Developments: Ongoing studies and trials to evaluate its effectiveness and safety for TGCT.
- Ripretinib Studies: New insights from the INSIGHT and INTRIGUE Phase 3 studies highlight the broader efficacy of Ripretinib in GIST patients.
Partnerships
- Zai Lab: Holds exclusive development and commercialization rights in Greater China for QINLOCK.
Clinical Trials and Research
- Deciphera has been actively involved in various clinical trials to explore and expand the potential uses of its drug candidates across multiple cancer indications.
Note: Information about specific revenue numbers and total employees is currently unavailable.
---
This report is based on publicly available data regarding Deciphera Pharmaceuticals, Inc. from 2024.
